Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 12, Issue 4 (2023)

Tocodynamic evaluation of dystocia affected canines after administration of uterotonic drugs

Author(s):
Prabhleen Singh, Ajeet Kumar, Ashwani Kumar Singh, Vijay Singh Malik and Mrigank Honparkhe
Abstract:
Dystocia is defined as the inability to expel pups through the birth canal without assistance which constitutes a major problem in the female dog. Cardiotocomonitor is useful for monitoring uterine contractions in response to uterotonic drugs. Thirty female dogs were randomly divided into three groups and the dogs of group 1 were administered 5% Dextrose infusion at rate of 1 g/kg b.w. slow intra-venous and 10% Calcium gluconate (Calcium-Sandoz®, Novartis India) at rate of 0.2 ml/kg b.w. intra-venous. In group 2, in addition to the treatment given in group 1, Oxytocin at rate of 0.5-1 IU/kg b.w. (Evatocin®, Oxytocin 5 IU per ml) was infused twenty minutes after calcium administration. In addition to the treatment given in groups 1 and 2, the dogs of group 3 were administered a total dose of 20 mg Nitroglycerine (Sigma Aldrich®, Nitroglycerine 200 mg per ml). The comparison between the groups was done by employing statistical analysis techniques which were based on haemato-biochemical parameters and cardiotocomonitor readings. No significant (p>0.05) difference in pre-treatment hemato-biochmical estimations was observed in all the groups. The number of contractions were significantly (p<0.05) more in groups 3 and 2 than in group 1 and the duration of contractions were significantly (p<0.05) more in group 3 than in groups 1 and 2. The amplitude of uterine contractions was significantly (p<0.05) higher in group 3 than in groups 1 and 2.
Pages: 1684-1687  |  302 Views  141 Downloads


The Pharma Innovation Journal
How to cite this article:
Prabhleen Singh, Ajeet Kumar, Ashwani Kumar Singh, Vijay Singh Malik, Mrigank Honparkhe. Tocodynamic evaluation of dystocia affected canines after administration of uterotonic drugs. Pharma Innovation 2023;12(4):1684-1687.

Call for book chapter